Effects and Safety of Sitagliptin in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Abstract Non-alcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease. However, the treatment is limited. The aim of this meta-analysis was to evaluate the effects and safety of sitagliptin, a selective inhibitor of dipeptidyl peptidase-4 (DPP-4I), in treating NAFLD. Studies were sourced from electronic databases including PubMed, CENTRAL (Cochrane Controlled Trials Register), Embase, Medline, Web of Science, Clinical Trials, and CNKI to identify all randomized controlled clinical trials (RCTs) and non-RCTs in adult patients with NAFLD. Key outcomes were changes in serum levels of liver enzymes and improvement in hepatic histology and fat content measured by imaging or liver biopsy. Stata14.0 and RevMan5.3 were used for the meta-analysis. Seven studies with 269 NAFLD patients were included. Compared to the control group, sitagliptin treatment improved serum gamma-glutamyl transpeptidase (GGT) levels in the RCT subgroup (SMD = 0.79, 95% CI: 0.01–1.58). However, there was no significant improvement in serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels following sitagliptin treatment. Four of the included studies performed liver imaging, but sitagliptin treatment did not result in a significant reduction in liver fat content. Only five participants developed sitagliptin-related gastrointestinal discomfort. Our study suggests that sitagliptin effects individuals with NAFLD by improving serum GGT. Although sitagliptin is safe and well tolerated in NAFLD patients, it exerts no beneficial effects on liver transaminase and liver fat content in these patients.

[1]  G. Costa,et al.  Incretin-based therapy and risk of cholangiocarcinoma: a nested case–control study in a population of subjects with type 2 diabetes , 2019, Acta Diabetologica.

[2]  S. N. Murthy,et al.  The incretin enhancer, sitagliptin, exacerbates expression of hepatic inflammatory markers in rats fed a high-cholesterol diet , 2019, Inflammation Research.

[3]  Z. Younossi,et al.  Predictors of nonalcoholic steatohepatitis and significant fibrosis in non‐obese nonalcoholic fatty liver disease , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[4]  R. Platt,et al.  Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study , 2018, British Medical Journal.

[5]  Z. Ni,et al.  Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway. , 2018, Experimental and therapeutic medicine.

[6]  S. Engel,et al.  Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials , 2018, Diabetes Therapy.

[7]  Shahinul Alam,et al.  Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial , 2018, Hepatic medicine : evidence and research.

[8]  A. Bitton,et al.  Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study , 2018, British Medical Journal.

[9]  P. Chakrabarti,et al.  Significance of circulatory DPP4 activity in metabolic diseases , 2018, IUBMB life.

[10]  D. Schuppan,et al.  Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis. , 2018, Antioxidants & redox signaling.

[11]  M. Yoneda,et al.  Current and future pharmacological therapies for NAFLD/NASH , 2017, Journal of Gastroenterology.

[12]  H. Yoshiji,et al.  Combined treatment with dipeptidyl peptidase‐4 inhibitor (sitagliptin) and angiotensin‐II type 1 receptor blocker (losartan) suppresses progression in a non‐diabetic rat model of steatohepatitis , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

[13]  K. Shimada,et al.  Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non‐alcoholic fatty liver disease and type 2 diabetes mellitus , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

[14]  D. Ayers,et al.  Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients , 2017, Current medical research and opinion.

[15]  Xin Sun,et al.  Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. , 2017, Clinics and research in hepatology and gastroenterology.

[16]  S. Sokar,et al.  Combination of Sitagliptin and Silymarin ameliorates liver fibrosis induced by carbon tetrachloride in rats. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[17]  J. Arrebola,et al.  Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy , 2017, Medicine.

[18]  T. Shen,et al.  The Effect of Sitagliptin on Lipid Metabolism of Fatty Liver Mice and Related Mechanisms , 2017, Medical science monitor : international medical journal of experimental and clinical research.

[19]  D. Panagiotakos,et al.  Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. , 2017, Metabolism: clinical and experimental.

[20]  F. Gueyffier,et al.  Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials. , 2017, Diabetes & metabolism.

[21]  C. McKenzie,et al.  Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. , 2017, World journal of gastroenterology.

[22]  M. Bruno,et al.  Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial , 2016, Diabetes Care.

[23]  Robert Blissett,et al.  The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe , 2016, Hepatology.

[24]  P. Pouwels,et al.  Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial , 2016, Diabetologia.

[25]  D. Brenner,et al.  Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. , 2016, Journal of hepatology.

[26]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[27]  S. Bulusu,et al.  What does serum γ-glutamyltransferase tell us as a cardiometabolic risk marker? , 2016, Annals of clinical biochemistry.

[28]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[29]  P. Angus,et al.  Incretin‐based therapies for the treatment of non‐alcoholic fatty liver disease: A systematic review and meta‐analysis , 2015, Journal of gastroenterology and hepatology.

[30]  K. Higuchi,et al.  Sitagliptin can inhibit the development of hepatic steatosis in high-fructose diet-fed ob/ob mice , 2015, Journal of clinical biochemistry and nutrition.

[31]  S. Seneff,et al.  Gamma-Glutamyltransferase: A Predictive Biomarker of Cellular Antioxidant Inadequacy and Disease Risk , 2015, Disease markers.

[32]  M. Moriguchi,et al.  Serum alanine aminotransferase predicts the histological course of non‐alcoholic steatohepatitis in Japanese patients , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[33]  C. Sirlin,et al.  Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[34]  R. Kream,et al.  Nitric Oxide Regulation of Mitochondrial Processes: Commonality in Medical Disorders. , 2015, Annals of transplantation.

[35]  H. Mitsui,et al.  Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury , 2015, SpringerPlus.

[36]  K. Cusi,et al.  The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease , 2015, Hepatology.

[37]  S. Schneeweiss,et al.  Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study , 2014, Annals of the rheumatic diseases.

[38]  Jiming Liu,et al.  Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range , 2014, BMC Medical Research Methodology.

[39]  M. Imamura,et al.  Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. , 2014, Hepato-gastroenterology.

[40]  J. Montastruc,et al.  Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database , 2013, Acta Diabetologica.

[41]  D. Drucker,et al.  Pharmacology, physiology, and mechanisms of incretin hormone action. , 2013, Cell metabolism.

[42]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[43]  Shahinul Alam,et al.  Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh. , 2013, World journal of hepatology.

[44]  J. Mclaughlin,et al.  Dipeptidyl peptidase-4 expression is reduced in Crohn's disease , 2012, Regulatory Peptides.

[45]  M. Duvnjak,et al.  Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. , 2012, World journal of gastroenterology.

[46]  M. Omata,et al.  The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone , 2012, TheScientificWorldJournal.

[47]  Michael Charlton,et al.  The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. , 2012, Gastroenterology.

[48]  K. Kotoh,et al.  Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. , 2011, Molecular medicine reports.

[49]  Christian Thoma,et al.  Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. , 2012, Journal of hepatology.

[50]  Y. Terauchi,et al.  Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus. , 2011, Hepato-gastroenterology.

[51]  T. Hibi,et al.  A case of drug-induced hepatic injury associated with sitagliptin. , 2011, Internal medicine.

[52]  A. Stang.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.

[53]  R. Cuddihy,et al.  Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial , 2010, The Lancet.

[54]  Yelena Wood,et al.  Elevated Hepatic Enzymes Potentially Associated with Sitagliptin , 2010, The Annals of pharmacotherapy.

[55]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[56]  Claire Bombardier,et al.  2009 Updated Method Guidelines for Systematic Reviews in the Cochrane Back Review Group , 2009, Spine.

[57]  F. Laine,et al.  Comparison of blood tests for liver fibrosis specific or not to NAFLD. , 2009, Journal of hepatology.

[58]  W. Goessling,et al.  Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. , 2008, Gastroenterology.

[59]  P. Korkusuz,et al.  Dipeptidyl peptidase IV (DDP IV) in NASH patients. , 2007, Annals of hepatology.

[60]  A. Lazenby,et al.  Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women , 2005, Hepatology.

[61]  Jeppe Sturis,et al.  One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. , 2004, Diabetes.

[62]  Huang Ji.  Dose conversion among different animals and healthy volunteers in pharmacological study , 2004 .

[63]  M. Galteau,et al.  Erythrocytes as targets for gamma‐glutamyltranspeptidase initiated pro‐oxidant reaction , 2002, European journal of haematology.